1. Home
  2. PHVS vs RDWR Comparison

PHVS vs RDWR Comparison

Compare PHVS & RDWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • RDWR
  • Stock Information
  • Founded
  • PHVS 2015
  • RDWR 1996
  • Country
  • PHVS Switzerland
  • RDWR Israel
  • Employees
  • PHVS N/A
  • RDWR N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • RDWR EDP Services
  • Sector
  • PHVS Health Care
  • RDWR Technology
  • Exchange
  • PHVS Nasdaq
  • RDWR Nasdaq
  • Market Cap
  • PHVS 980.9M
  • RDWR 1.3B
  • IPO Year
  • PHVS 2021
  • RDWR 1999
  • Fundamental
  • Price
  • PHVS $22.32
  • RDWR $28.56
  • Analyst Decision
  • PHVS Buy
  • RDWR Hold
  • Analyst Count
  • PHVS 6
  • RDWR 4
  • Target Price
  • PHVS $37.17
  • RDWR $27.00
  • AVG Volume (30 Days)
  • PHVS 33.8K
  • RDWR 502.3K
  • Earning Date
  • PHVS 08-13-2025
  • RDWR 07-30-2025
  • Dividend Yield
  • PHVS N/A
  • RDWR N/A
  • EPS Growth
  • PHVS N/A
  • RDWR N/A
  • EPS
  • PHVS N/A
  • RDWR 0.27
  • Revenue
  • PHVS N/A
  • RDWR $281,874,000.00
  • Revenue This Year
  • PHVS N/A
  • RDWR $10.38
  • Revenue Next Year
  • PHVS N/A
  • RDWR $7.14
  • P/E Ratio
  • PHVS N/A
  • RDWR $105.94
  • Revenue Growth
  • PHVS N/A
  • RDWR 9.54
  • 52 Week Low
  • PHVS $11.51
  • RDWR $17.36
  • 52 Week High
  • PHVS $25.76
  • RDWR $31.57
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 73.31
  • RDWR 56.21
  • Support Level
  • PHVS $17.63
  • RDWR $29.00
  • Resistance Level
  • PHVS $19.00
  • RDWR $31.57
  • Average True Range (ATR)
  • PHVS 1.20
  • RDWR 0.80
  • MACD
  • PHVS 0.35
  • RDWR -0.15
  • Stochastic Oscillator
  • PHVS 92.15
  • RDWR 33.11

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About RDWR Radware Ltd.

Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.

Share on Social Networks: